
Amylyx Pharmaceuticals, Inc.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Amylyx Pharmaceuticals develops and commercializes therapies for neurodegenerative diseases, including treatments studied for ALS and progressive supranuclear palsy. The company markets and researches drug candidates aimed at slowing disease progression in patients with limited treatment options.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| MILNE GEORGE M JRInsider | Sell | $831K | 30,000at $27.70 | Oct 5, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable AMLX activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.